• Researcher Profile

    George P. Canellos, MD

    George P. Canellos, MD

    Top Doctor

    Institute Physician

    William Rosenberg Professor of Medicine, Harvard Medical School


    Hematologic Oncology

    Office phone: 617-632-3470
    Fax: 617-632-3477
    Email: george_canellos@dfci.harvard.edu

    Preferred contact method: appointment phone

    View Physician Profile

    Research Department

    Medical Oncology/Hematologic Malignancies


    Lymphoma, Chronic lymphocytic leukemia

    Area of Research

    Diagnosis and Treatment of Lymphoma

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1B14
    Boston, MA 02215


    Dr. Canellos received his MD in 1960 from Columbia University. After internship and residency at Massachusetts General Hospital, he was a clinical associate at the National Cancer Institute and a research fellow at the Royal Postgraduate Medical School in London. From 1975 to 1995, he served as chief of DFCI's Division of Medical Oncology and as medical director for network development for Dana-Farber/Partners CancerCare. He is currently a senior physician at DFCI and Brigham and Women's Hospital. He is the former Editor-in-Chief of the Journal of Clinical Oncology and President of the American Society of Clinical Oncology.

    Recent Awards

    • Karl Musshof Award from the 7th International Hodgkin Lymphoma Symposium, 2007
    • Statesman Award, American Society of Clinical Oncology, 2007
    • Frank S. Moran Clinical Research Award, University of Michigan Cancer Center, 2006
    • San Salvatore Foundation Award at the 9th International Conference on Lymphoma., 2005
    • Ellis Island Foundation Medal of Honor, 2004
    • Key to the Cure Award, The Cure for Lymphoma Foundation, 1999
    • Honorary Doctor of Science, University of Athens, Greece, 1997
    • Distinguished Service Award for Scientific Achievement, American Society of Clinical Oncology, 1996
    • Fellowship, Royal College of Physicians London and Edinburgh, 1991


    Diagnosis and Treatment of Lymphoma

    Our research interests span a broad area of cytotoxic chemotherapeutic agents as well as biological agents for the treatment of malignant diseases.

    As former chair of the Lymphoma Committee of the Cancer and Leukemia Group B, a national cooperative trials group, Dr. Canellos initiated clinical trials in close collaboration with other groups. These trials search for answers concerning many issues, such as:

    -The optimal tolerable chemotherapy regimen for the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma
    - The integration of antibody therapy with cytotoxic agents for the treatment of these diseases
    - The role of early high-dose autologous transplantation in the management of poor-prognosis patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.

    In addition, new initiatives are under way in the use of radioimmunotherapy combined with cytotoxic therapy and the development of new agents for the treatment of lymphoma. We are exploring diagnostics to define the presence of residual disease using positron emission tomographic (PET) scans and a comparison with gallium/single photon emission computed tomography. SPECT was pioneered at DFCI for the treatment of lymphoma, and has helped to identify those patients at particularly high risk following cytotoxic treatment.He continues to be the "senior statesman" in the lymphoma group.

    Select Publications

    • Friedberg JW, Fischman A, Neuberg D, Takvorian T, Mauch P, Canellos G, Van Den Abbele. FDG -PET is superior in staging and more sensitive in Hodgkin lymphoma. Leuk Lymphoma 2004;45:85-92.
    • Canellos GP, Duggan D, Johnson J, Niedzwiecki D. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
      J Clin Oncol 2004;22:1532-3.

    • Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
      Cancer 2004;100:1438-48.
    • Canellos GP. Lymphoma: present and future challenges. Semin Hematol 2004;41(suppl 7):26-31.
    • Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
    • Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003;14:268-72.
    • Miklos D, Canellos G. Non-Hodgkin's lymphoma (NHL). In: Thomas ED, Nathan DG, Goldman JM, editors. Classic papers in hematological oncology. London: Taylor and Francis; 2003. p.251-71.
      CanellosGP, Lister T.A.,Young B., The Lymphomas,edition2,Elsevier 2006
    • Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin's disease. Cancer 2003;98:978-82.
    • Friedberg JW, Aster JC, Canellos GP. Hodgkin's disease. In: Handin RI, Lux SE IV, Stossel TP, editors. Blood - principles and practice of hematology. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2003. p.837-60.
    • Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin's lymphoma: a blinded comparison. Leuk Lymphoma 2004;45:85-92.
View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now